Xilio Therapeutics (XLO) Total Liabilities (2020 - 2026)
Xilio Therapeutics (XLO) posted Total Liabilities of $90.9 million for Q1 2026, down 23.84% sequentially from $119.4 million in Q4 2025, and down 2.23% YoY from $93.0 million in Q1 2025.
Xilio Therapeutics (XLO) Total Liabilities (2020 - 2026) Analysis & Trends
Xilio Therapeutics has reported Total Liabilities for 7 years, with the latest figure at $90.9 million in Q1 2026.
- Quarterly Total Liabilities fell 2.23% year-over-year to $90.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $90.9 million (down 2.23% YoY) and the FY2025 annual result came in at $119.4 million, up 123.3% from the prior year.
- Total Liabilities slipped to $90.9 million in Q1 2026 per XLO's latest filing, from $119.4 million in the prior quarter.
- Over five years, Total Liabilities peaked at $141.8 million in Q3 2025 and troughed at $24.1 million in Q4 2023.
- A 5-year average of $60.1 million and a median of $53.5 million in 2024 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2023 and 2025: Total Liabilities retreated 28.1% in 2023, then surged 164.12% in 2025.
- Over 5 years, Total Liabilities stood at $33.5 million in 2022, then declined by 28.1% to $24.1 million in 2023, then surged by 121.91% to $53.5 million in 2024, then surged by 123.3% to $119.4 million in 2025, then fell by 23.84% to $90.9 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $90.9 million, $119.4 million, and $141.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.80 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.53 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.33 Bn | 60.14 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 59.76 Bn | 54.62 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.84 Bn | 28.53 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.23 Bn | 9.84 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.29 Bn | 26.46 Bn | - | 10.03 Bn |
| 10 | Xilio Therapeutics | 178.33 Mn | 42.29 Mn | - | 81.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 81.99 Mn |
| Mar 31, 2026 | 90.94 Mn |
| Dec 31, 2025 | 119.41 Mn |
| Sep 30, 2025 | 141.79 Mn |
| Jun 30, 2025 | 126.74 Mn |
| Mar 31, 2025 | 93.02 Mn |
| Dec 31, 2024 | 53.48 Mn |
| Sep 30, 2024 | 53.68 Mn |
| Jun 30, 2024 | 56.46 Mn |
| Mar 31, 2024 | 56.84 Mn |
| Dec 31, 2023 | 24.10 Mn |
| Sep 30, 2023 | 25.34 Mn |
| Jun 30, 2023 | 24.98 Mn |
| Mar 31, 2023 | 26.71 Mn |
| Dec 31, 2022 | 33.52 Mn |
| Sep 30, 2022 | 31.12 Mn |
| Jun 30, 2022 | 33.91 Mn |
| Mar 31, 2022 | 30.23 Mn |
| Dec 31, 2021 | 32.63 Mn |
| Sep 30, 2021 | 34.29 Mn |